On April 30, 2018 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported that it will host a conference call and live webcast to report its 2018 first quarter financial results on Wednesday, May 9, 2018 at 4:30 p.m. ET (Press release, Inovio, APR 30, 2018, View Source [SID1234525832]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived version of the audio presentation will be available online at View Source This is a listen-only event but will include a live Q&A with analysts.

A replay of the conference call will be accessible two hours after the call at 877-481-4010 (domestic) or 919-882-2331 (international) using replay ID 29009.

On April 30, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that it will report financial results for the third quarter of fiscal 2018 and hold a conference call to discuss those results on Wednesday, May 9, 2018 (Press release, Array BioPharma, APR 30, 2018, View Source;p=RssLanding&cat=news&id=2345678 [SID1234525849]). Ron Squarer, Chief Executive Officer, will lead the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, May 9, 2018

Time: 9:00 a.m. Eastern Time

Toll-Free: (844) 464-3927

Toll: (765) 507-2598

Pass Code: 6465079

Webcast, including Replay and Conference Call Slides:
View Source

On April 30, 2018 McKesson Corporation (NYSE:MCK) reported that it will release financial results for its fourth fiscal quarter ended March 31, 2018 on Thursday, May 24, 2018, prior to the opening of trading on the New York Stock Exchange (Press release, McKesson, APR 30, 2018, View Source [SID1234525868]). The company has scheduled a conference call for 8:00 AM Eastern Time (5:00 AM Pacific Time), during which John Hammergren, chairman and chief executive officer, and Britt Vitalone, executive vice president and chief financial officer, will review these results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in number for individuals wishing to participate on the call is 323-701-0225. Craig Mercer, senior vice president, Investor Relations is the leader of the call and the password is ‘McKesson’. The conference call will also be available live and archived on the company’s Investor Relations website at View Source

Zai Laboratory has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 20-F, Zai Laboratory, 2018, APR 30, 2018, View Source [SID1234527579]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 30, 2018 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, reported that David Hansen, MabVax’s President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on May 3, 2018 (Press release, MabVax, APR 30, 2018, View Source [SID1234525833]). The following are the details to access the presentation:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

View investor presentations 24/7 at www.virtualinvestorconferences.com . (PRNewsFoto/OTC Markets Group Inc.)

DATE: Thursday, May 3, 2018
TIME: 10:45 a.m. EDT
LINK: View Source

As part of his presentation, Mr. Hansen will provide a corporate overview, as well as a clinical update and outline anticipated milestones for its Phase 1 clinical programs including the MVT-5873 clinical trial in combination with a standard of care chemotherapy as a first line therapy for patients newly diagnosed with pancreatic cancer, and the MVT-1075 radioimmunotherapy clinical trial for the treatment of pancreatic, colon and lung cancers.

VirtualInvestorConferences.com is a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the association’s "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days. It is recommended that investors pre-register to save time and receive event updates.

A link to VirtualInvestorConferences.com event will also be available by accessing the MabVax’s IR Calendar in the Investors section of the Company’s website (www.mabvax.com).

About VirtualInvestorConferences.com

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network. To learn more, please visit www.VirtualInvestorConferences.com